Cargando…
Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications
Endometrial cancer (EC) is the most frequent gynecological cancer. In patients with relapsed and advanced disease, prognosis is still dismal and development of resistance is common. In this context, endometrial Cancer Stem Cells (eCSC), stem-like cells capable to self-renewal and differentiation in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896186/ https://www.ncbi.nlm.nih.gov/pubmed/31752447 http://dx.doi.org/10.3390/cancers11111820 |
_version_ | 1783476726866640896 |
---|---|
author | Giannone, Gaia Attademo, Laura Scotto, Giulia Genta, Sofia Ghisoni, Eleonora Tuninetti, Valentina Aglietta, Massimo Pignata, Sandro Valabrega, Giorgio |
author_facet | Giannone, Gaia Attademo, Laura Scotto, Giulia Genta, Sofia Ghisoni, Eleonora Tuninetti, Valentina Aglietta, Massimo Pignata, Sandro Valabrega, Giorgio |
author_sort | Giannone, Gaia |
collection | PubMed |
description | Endometrial cancer (EC) is the most frequent gynecological cancer. In patients with relapsed and advanced disease, prognosis is still dismal and development of resistance is common. In this context, endometrial Cancer Stem Cells (eCSC), stem-like cells capable to self-renewal and differentiation in mature cancer cells, represent a potential field of expansion for drug development. The aim of this review is to characterize the role of eCSC in EC, their features and how they could be targeted. CSC are involved in progression, invasiveness and metastasis (though epithelial to mesenchimal transition, EMT), as well as chemoresistance in EC. Nevertheless, isolation of eCSC is still controversial. Indeed, CD133, Aldheyde dehydrogenase (ALDH), CD117, CD55 and CD44 are enriched in CSCs but there is no universal marker nowadays. The most frequently activated pathways in eCSC are Wingless-INT (Wnt)/β-catenin, Notch1, and Hedghog, with a high expression of self-renewal transcription factors like Octamer binding transcription factor 4 (OCT), B Lymphoma Mo-MLV Insertion Region 1 Homolog (BMI1), North American Network Operations Group Homebox protein (NANOG), and SRY-Box 2 (SOX2). These pathways have been targeted with selective drugs alone or in combination with chemotherapy and immunotherapy. Unfortunately, although preclinical results are encouraging, few clinical data are available. |
format | Online Article Text |
id | pubmed-6896186 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68961862019-12-23 Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications Giannone, Gaia Attademo, Laura Scotto, Giulia Genta, Sofia Ghisoni, Eleonora Tuninetti, Valentina Aglietta, Massimo Pignata, Sandro Valabrega, Giorgio Cancers (Basel) Review Endometrial cancer (EC) is the most frequent gynecological cancer. In patients with relapsed and advanced disease, prognosis is still dismal and development of resistance is common. In this context, endometrial Cancer Stem Cells (eCSC), stem-like cells capable to self-renewal and differentiation in mature cancer cells, represent a potential field of expansion for drug development. The aim of this review is to characterize the role of eCSC in EC, their features and how they could be targeted. CSC are involved in progression, invasiveness and metastasis (though epithelial to mesenchimal transition, EMT), as well as chemoresistance in EC. Nevertheless, isolation of eCSC is still controversial. Indeed, CD133, Aldheyde dehydrogenase (ALDH), CD117, CD55 and CD44 are enriched in CSCs but there is no universal marker nowadays. The most frequently activated pathways in eCSC are Wingless-INT (Wnt)/β-catenin, Notch1, and Hedghog, with a high expression of self-renewal transcription factors like Octamer binding transcription factor 4 (OCT), B Lymphoma Mo-MLV Insertion Region 1 Homolog (BMI1), North American Network Operations Group Homebox protein (NANOG), and SRY-Box 2 (SOX2). These pathways have been targeted with selective drugs alone or in combination with chemotherapy and immunotherapy. Unfortunately, although preclinical results are encouraging, few clinical data are available. MDPI 2019-11-19 /pmc/articles/PMC6896186/ /pubmed/31752447 http://dx.doi.org/10.3390/cancers11111820 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Giannone, Gaia Attademo, Laura Scotto, Giulia Genta, Sofia Ghisoni, Eleonora Tuninetti, Valentina Aglietta, Massimo Pignata, Sandro Valabrega, Giorgio Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications |
title | Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications |
title_full | Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications |
title_fullStr | Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications |
title_full_unstemmed | Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications |
title_short | Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications |
title_sort | endometrial cancer stem cells: role, characterization and therapeutic implications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6896186/ https://www.ncbi.nlm.nih.gov/pubmed/31752447 http://dx.doi.org/10.3390/cancers11111820 |
work_keys_str_mv | AT giannonegaia endometrialcancerstemcellsrolecharacterizationandtherapeuticimplications AT attademolaura endometrialcancerstemcellsrolecharacterizationandtherapeuticimplications AT scottogiulia endometrialcancerstemcellsrolecharacterizationandtherapeuticimplications AT gentasofia endometrialcancerstemcellsrolecharacterizationandtherapeuticimplications AT ghisonieleonora endometrialcancerstemcellsrolecharacterizationandtherapeuticimplications AT tuninettivalentina endometrialcancerstemcellsrolecharacterizationandtherapeuticimplications AT agliettamassimo endometrialcancerstemcellsrolecharacterizationandtherapeuticimplications AT pignatasandro endometrialcancerstemcellsrolecharacterizationandtherapeuticimplications AT valabregagiorgio endometrialcancerstemcellsrolecharacterizationandtherapeuticimplications |